Your browser doesn't support javascript.
loading
Brief Report: Potent clinical and radiological response to larotrectinib in TRK fusion-driven high-grade glioma.
Ziegler, David S; Wong, Marie; Mayoh, Chelsea; Kumar, Amit; Tsoli, Maria; Mould, Emily; Tyrrell, Vanessa; Khuong-Quang, Dong-Anh; Pinese, Mark; Gayevskiy, Velimir; Cohn, Richard J; Lau, Loretta M S; Reynolds, Mark; Cox, Michael C; Gifford, Andrew; Rodriguez, Michael; Cowley, Mark J; Ekert, Paul G; Marshall, Glenn M; Haber, Michelle.
Afiliación
  • Ziegler DS; Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia. d.ziegler@unsw.edu.au.
  • Wong M; Children's Cancer Institute, UNSW, Sydney, NSW, Australia. d.ziegler@unsw.edu.au.
  • Mayoh C; Kinghorn Centre for Clinical Genomics, Garvan Institute, Sydney, NSW, Australia.
  • Kumar A; Children's Cancer Institute, UNSW, Sydney, NSW, Australia.
  • Tsoli M; Children's Cancer Institute, UNSW, Sydney, NSW, Australia.
  • Mould E; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Tyrrell V; Children's Cancer Institute, UNSW, Sydney, NSW, Australia.
  • Khuong-Quang DA; Children's Cancer Institute, UNSW, Sydney, NSW, Australia.
  • Pinese M; Children's Cancer Institute, UNSW, Sydney, NSW, Australia.
  • Gayevskiy V; Murdoch Children's Research Institute, Royal Children's Hospital, The University of Melbourne, Melbourne, VIC, Australia.
  • Cohn RJ; Kinghorn Centre for Clinical Genomics, Garvan Institute, Sydney, NSW, Australia.
  • Lau LMS; Kinghorn Centre for Clinical Genomics, Garvan Institute, Sydney, NSW, Australia.
  • Reynolds M; Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia.
  • Cox MC; Children's Cancer Institute, UNSW, Sydney, NSW, Australia.
  • Gifford A; Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia.
  • Rodriguez M; Clinical Development, Loxo Oncology, Inc., South San Francisco, San Francisco, CA, USA.
  • Cowley MJ; Clinical Development, Loxo Oncology, Inc., South San Francisco, San Francisco, CA, USA.
  • Ekert PG; Children's Cancer Institute, UNSW, Sydney, NSW, Australia.
  • Marshall GM; Department of Anatomical Pathology, Prince of Wales Hospital, Randwick, NSW, Australia.
  • Haber M; Department of Anatomical Pathology, Prince of Wales Hospital, Randwick, NSW, Australia.
Br J Cancer ; 119(6): 693-696, 2018 09.
Article en En | MEDLINE | ID: mdl-30220707
ABSTRACT
Genes encoding TRK are oncogenic drivers in multiple tumour types including infantile fibrosarcoma, papillary thyroid cancer and high-grade gliomas (HGG). TRK fusions have a critical role in tumourigenesis in 40% of infant HGG. Here we report the first case of a TRK fusion-driven HGG treated with larotrectinib-the first selective pan-TRK inhibitor in clinical development. This 3-year-old girl had failed multiple therapies including chemotherapy and radiotherapy. Tumour profiling confirmed an ETV6-NTRK3 fusion. Treatment with larotrectinib led to rapid clinical improvement with near total resolution of primary and metastatic lesions on MRI imaging. This is the first report of a TRK fusion glioma successfully treated with a TRK inhibitor.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirazoles / Pirimidinas / Neoplasias Encefálicas / Glioma Límite: Child, preschool / Female / Humans Idioma: En Revista: Br J Cancer Año: 2018 Tipo del documento: Article País de afiliación: Australia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirazoles / Pirimidinas / Neoplasias Encefálicas / Glioma Límite: Child, preschool / Female / Humans Idioma: En Revista: Br J Cancer Año: 2018 Tipo del documento: Article País de afiliación: Australia